SAMANTREE-MEDICAL
14.5.2019 12:43:07 CEST | Business Wire | Press release
SamanTree Medical, committed to reducing the need for cancer surgery re-operation particularly in breast surgery, announced today the successful closing of its CHF 9.5 million Series A financing. Proceeds will be used to commercialize the patented Histolog™ system, notably the recently CE mark Histolog™ Scanner v2, for enabling precise tumor removal at first surgery.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190514005476/en/
Panakès Partners, the Medtech European leading venture capital mixing strong corporate and investment expertise, has led this round, alongside the Sioux Tech Fund, the venture arm of Sioux Technologies, a company with expertise in high-tech manufacturing, software development and data analytics. Existing shareholders and new investors BOM Brabant Ventures and btov Partners were participating as well.
“The timing is impeccable with the recently awarded European project, we are combining the right supports for executing on our mission to bring the gold standard in the Operating Room” said CEO and Co-Founder Bastien Rachet. The European Innovation Council awarded SamanTree Medical with EUR 2.3 million grant in September 2018, via its H2020 SME’s Instrument Program.
More than 500,000 lumpectomies are performed annually in the USA and Europe alone and up to 25% require re-operation. Additional operation is a burden for the patient and it increases the stress relative to the treatment; it also results in annual costs of $2.7 billion. Surgeons face a difficult trade-off: maximize confidence in removal of the entire tumor and minimize removal of healthy tissue. The “Gold Standard” for margin assessment is histopathology microscopy – these laboratory results, however, aren’t available until days after surgery. Surgeons need faster support for margin assessment in the operating room, ideally in real-time and with accuracy comparable to this “Gold Standard”.
SamanTree’s Histolog™ is the only solution that enables a global mapping of a lumpectomy for full margin control with histology-grade confidence in few minutes before closing the incision. With this innovative and highly practical imaging modality, the clinician is one touch-on-the-screen away from visualizing cancerous cell on a surgical specimen immediately during surgery. Enhancing the decision-making process during the surgery, this solution carries the promise of a better patient care, by increasing the confidence in a complete tumor removal at first surgery.
About SamanTree Medical
SamanTree Medical, a spin-off
company from the Swiss Federal Institute of Technology (EPFL), develops
disruptive imaging modalities and data analytic solutions for improving
cancer treatment care. Founded in December 2014, SamanTree is
headquartered in Lausanne, Switzerland. www.samantree.com
About Panakès Partners
Panakès Partners is a Venture Capital
investor that finances medical companies, early stage startups and SMEs,
with extremely promising products and great ambition, in Europe and
Israel, improving both patient outcomes and healthcare economics.
Investments focus on the medical device, diagnostics and healthcare IT
fields. Panakès Partners is headquartered in Milan, Italy.
www.panakes.it
/ Contact: contact@panakes.it
About the Sioux Tech Fund
The investment fund of high-tech
company Sioux Technologies, together with regional and European partners
(such as the Brabant Development Agency and the European Angel Fund),
invests in promising technical start-ups. This gives innovative ideas a
chance for faster development in terms of technological progress and
faster market introduction.
www.sioux.eu
/ Contact: info@sioux.eu
About BOM Brabant Ventures
BOM (the Brabant Development
Agency) works together with entrepreneurs to create a strong,
sustainable, and future-proof Brabant economy. BOM uses the Brabant
Ventures label to focus, using knowledge and capital, on the accelerated
and future-proof growth of ambitious Brabant startups and scaleups in
the high-tech systems and software, agri-food, life sciences & health,
maintenance, supply chain, and bio-based economy top industries.
www.bom.nl
/ Contact: info@bom.nl
SamanTree Medical has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No.823284.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190514005476/en/
Contact:
For more information regarding this press release, please contact: Florence Besnier, Executive Office Manager +41 21 625 09 40 Email: info@samantree.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF Reports Fourth Quarter and Full Year 2025 Results11.2.2026 22:36:00 CET | Press release
Delivered solid top and bottom-line performance & advanced strategic priorities in 2025Launched sale process for the Food Ingredients segmentContinuing to drive financial performance in 2026 International Flavors & Fragrances Inc. (NYSE: IFF) reported financial results for the fourth quarter and full year ended December 31, 2025. Full year 2025 Consolidated Summary: Management Commentary “IFF delivered a solid 2025 performance, meeting the full-year financial commitments we set at the start of the year, despite a challenging operating environment,” said Erik Fyrwald, CEO of IFF. “It was also a year of continued strategic progress. We invested in R&D, commercial capabilities, and capacity expansion to better serve customers, advance our innovation pipeline, and support future profitable growth.” “We also took steps to optimize our portfolio. Through several divestitures and the recent launch of a sale process for our Food Ingredients segment, we sharpened our strategic focus and improve
Grid Dynamics Accelerates AI Transformation Momentum11.2.2026 22:05:00 CET | Press release
Earns Preferred Vendor Status at a Top-Tier Hyperscaler; 2025 AI Revenue Grew 30% Year-Over-YearKey Takeaways: Achieved Preferred Vendor status with a top-tier hyperscaler, opening up a significantly larger revenue opportunity for Grid Dynamics. In 2025, Grid Dynamics achieved 30% year-over-year AI revenue growth. Partners increasingly rely on Grid Dynamics to deliver next-generation AI capabilities to global clients, supporting continued AI revenue growth. Grid Dynamics Holdings, Inc. (Nasdaq: GDYN) (“Grid Dynamics”), a premier AI transformation partner for the Fortune 1000, today announced it has achieved Preferred Vendor status with one of the major hyperscale cloud providers. This milestone follows a strategic, exhaustive two-year vendor consolidation initiative by the hyperscaler that reduced its service provider ecosystem to a small group. This designation establishes the contractual framework for Grid Dynamics to significantly increase business with this hyperscaler, boosting Gr
Altasciences Announces Chris Perkin Appointed Executive Chairman; Marie-Hélène Raigneau Appointed Chief Executive Officer11.2.2026 21:14:00 CET | Press release
Altasciences announced today that Chris Perkin has been appointed Executive Chairman of the company’s Board of Directors, effective Tuesday, February 24, 2026. Following a leadership transition that has been underway for the past 12 months, Marie-Hélène Raigneau, President of the company since April 2025, has been appointed Chief Executive Officer, also effective Tuesday, February 24, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260211203073/en/ From left to right: Chris Perkin, Executive Chairman of the Board (Altasciences), and Marie-Hélène Raigneau, Chief Executive Officer (Altasciences). “Having worked alongside Marie-Hélène for over two decades, I am fully confident in her readiness to guide Altasciences forward with clarity and purpose,” said Chris. “I am happy to be stepping aside after 50 years in drug development, knowing that Altasciences is well-positioned for the future.” Chris joined Altasciences as CEO
Sodali & Co Hires BlackRock Investment Stewardship AI and Data Lead11.2.2026 20:20:00 CET | Press release
Brett Miller to lead the firm’s global AI, data and insight offering Sodali & Co, the leading global capital markets-centric stakeholder advisory firm, is pleased to announce that Brett Miller has joined the firm as Global Head of Data Analytics based in New York. Miller joins from BlackRock where he served as Head of Data Analytics for its Investment Stewardship team. In his new role, Miller will lead Sodali’s global AI and data analytics strategy and embed data-driven insight across the firm’s integrated Shareholder Services, Sustainability, and Strategic Communications offering to help support clients navigate the increasingly complex and interconnected governance, investor, and stakeholder landscape. Miller joins Sodali & Co. at a time when investors are rapidly leveraging data and AI to drive investment and voting decisions. He will lead the buildout of an advanced analytics and technology platform to give clients actionable insight into how their narrative is driving capital flow
Andersen Consulting tilføjer Lighthouse Consultants11.2.2026 20:16:00 CET | Pressemeddelelse
Andersen Consulting indgår en samarbejdsaftale med Lighthouse Consultants, et London-baseret konsulentfirma med speciale i retsmedicinsk regnskab og finansielle undersøgelser. Lighthouse Consultants blev stiftet af administrerende direktør Kingsley Bye og leverer ydelser, der omfatter efterforskning af svindel og økonomisk kriminalitet, undersøgelser af bestikkelse og korruption, analyse af retssager og forsikringskrav, finansiel analyse, risikovurderinger, interne revisioner og compliance-gennemgange samt bæredygtighedsrevisioner. Virksomhedens team af erfarne statsautoriserede revisorer arbejder sammen med advokatfirmaer, formuende privatpersoner, virksomheder og velgørende organisationer med henblik på at løse komplekse tvister, mindske risici og øge gennemsigtigheden i finansielle og operationelle processer. "Ved at integrere vores retsmedicinske og efterforskningsmæssige ekspertise med Andersens globale platform kan vi levere en mere omfattende pakke af ydelser, der imødekommer ku
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom